Category Archives: Global News Feed

NEW YORK and LEAMINGTON, Ontario, Sept. 23, 2022 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (“Tilray” or the “Company”) (Nasdaq: TLRY; TSX: TLRY), a leading global cannabis-lifestyle and consumer packaged goods company inspiring and empowering the worldwide community to live their very best life, today announced that the Company will release financial results for its first quarter fiscal 2023 ended August 31, 2022 on October 7, 2022 at 8:30 an Eastern Time.

See the original post:
Tilray Brands, Inc. to Announce First Quarter Fiscal 2023 Financial Results on October 7, 2022

HAV™ was utilized to treat multiple patients suffering from shrapnel, gunshot wounds, and mine blast injuries HAV™ was utilized to treat multiple patients suffering from shrapnel, gunshot wounds, and mine blast injuries

Excerpt from:
Humacyte Announces Presentations by Ukrainian Surgeons on Use of the Human Acellular Vessel™ to Treat Wartime Vascular Trauma at the European...

SAN DIEGO, Sept. 23, 2022 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a San Diego based clinical stage biopharmaceutical drug development company targeting currently untreatable eye diseases, today announced that the 1-year interim data from the 2-year Phase 1b/2 trial of LBS-008 in adolescent STGD1 will be presented at the “Late Breaking Development” session at the American Academy of Ophthalmology Annual Meeting (AAO 2022) being held September 30 – October 3, 2022 in Chicago.

View post:
Belite Bio Announces Late-Breaking Presentation at the American Academy of Ophthalmology 2022 Annual Meeting

SYDNEY, AUSTRALIA, Sept. 23, 2022 (GLOBE NEWSWIRE) --  Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune diseases, is pleased to announce it has received a €1,804,341 (~ A$2,693,046 ) research and development (R&D) tax incentive payment in cash from the French Government under its Crédit d’Impôt Recherche scheme (CIR).

Go here to read the rest:
Immutep Receives A$2.7 million R&D Tax Incentive from French Government

REDWOOD CITY, Calif., Sept. 23, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that data from the OPTIC trial of ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022) in wet age-related macular degeneration (wet AMD) will be presented next week during the Late Breaking Developments portion of Retinal Subspecialty Day at the American Academy of Ophthalmology (AAO) 2022 Annual Meeting in Chicago, Illinois. In addition to reviewing the durable efficacy and safety demonstrated out to 104 weeks in the OPTIC Study, the presentation will include new analyses of intraretinal fluid (IRF) and subretinal fluid (SRF) after a single, in-office, intravitreal (IVT) injection of Ixo-vec in subjects requiring frequent anti-VEGF injections for their wet AMD.

See the article here:
Adverum Biotechnologies Announces Upcoming Data Presentation at AAO 2022

REDWOOD CITY, Calif., Sept. 23, 2022 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ: JSPR), a biotechnology company focused on enabling cures with stem cell therapies, today announced that the Company will be participating in the following conferences in September.

Original post:
Jasper Therapeutics to Present at Upcoming Conferences

ILUVIEN or faricimab (6.0 mg) injections versus observation will be studied for the prevention of visual acuity loss due to radiation retinopathy ILUVIEN or faricimab (6.0 mg) injections versus observation will be studied for the prevention of visual acuity loss due to radiation retinopathy

See the original post:
Alimera Announces Agreement with Jaeb Center for Health Research on Behalf of the DRCR Retina Network

SEATTLE, Sept. 23, 2022 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced the company will be participating in the upcoming Capital One Spatial Biology & Proteomics Summit taking place virtually on Wednesday, September 28, 2022.

Read more:
Nautilus Biotechnology to Participate in the Capital One Spatial Biology & Proteomics Summit

-- Book developed in collaboration with the Bardet-Biedl Syndrome Foundation ---- BBS Global Day on Sept. 24 coordinated by BBS International --

See original here:
Rhythm Pharmaceuticals Announces Publication of Children’s Book for Patients and Families Living with Bardet-Biedl Syndrome (BBS)

SOUTH SAN FRANCISCO, Calif., Sept. 23, 2022 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced that management plans to present at the Jefferies Cell and Genetic Medicine Summit on Friday, September 30, 2022 at 6:30AM Pacific Time/9:30AM Eastern Time.

Read the rest here:
Allogene Therapeutics Announces Participation in the Jefferies Cell and Genetic Medicine Summit